New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 42 new drugs as per the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-diabetes, anti-hypertension, antibiotics and anti-inflammatory drugs.
While the Authority’s latest meeting considered 43 applications for retail price fixation of new drugs, an application by Indoco Remedies for a particular strength of amoxycillin and potassium clavulanate tablets has been deferred for re-examination of data before retail price fixation.
The price fixation for the product was deferred in the previous meeting also, and the company has submitted its representation following that. The matter is under examination, said NPPA.
The formulations for which the retail prices has been fixed include meropenem and sulbactam for injection – anti-bacterial injection for treatment of skin and abdominal infections – in which each vial contains meropenem trihydrate equivalent to anhydrous meropenem 1000 mg, sodium (as sodium carbonate) 90.2 mg, sulbactam sodium equivalent to sulbactam 500 mg, marketed by Zydus Healthcare Ltd, at Rs. 1,938.59 per vial.
Retail price of antibiotic combination ceftriaxone 1000 mg and tazobactam 125 mg injection from FDC Ltd has been notified at Rs. 199.26 per vial; mycophenolate mofetil 750 mg tablets from Ipca Laboratories at Rs. 131.58 per tablet; and clarithromycin 1000 mg extended release tablets from Abbott Healthcare Pvt Ltd, at Rs. 71.71 per tablet.
The Authority has also fixed the price of antibiotic combination ofloxacin and metronidazole oral suspension containing ofloxacin 100 mg and metronidazole benzoate equivalent to metronidazole 200 mg from Alkem Laboratories; and ofloxacin 100 mg and metronidazole 200 mg combination from Abbott Healthcare, at Rs. 1.04 per 1 ml, each; and antibiotic cefixime and ofloxacin oral suspension containing cefixime IP as trihydrate equivalent to anhydrous cefixime 50mg ofloxacin 50mg from FDC Ltd at Rs. 2 per ml.
Retail price of various drugs to address issues related to hypertension and diabetes has also been fixed during the Authority meeting held on August 28, 2025. The prices have also been notified by the Authority following the meeting.
Price of particular strengths of dapagliflozin, glimepiride & metformin hydrochloride extended release from Dr Reddy’s Laboratories; empagliflozin, linagliptin and metformin hydrochloride extended release tablets from Natco Pharma, empagliflozin, sitagliptin and metformin hydrochloride extended release tablets from Cadila Pharmaceuticals, and MSN Laboratories were also fixed during the meeting.
Retail price of blood pressure drug formulations at particular strengths, of telmisartan and amlodipine combinations from Primus Remedies, and Workcell Solutions; amlodipine and bisoprolol fumarate tablets from Torrent Pharmaceuticals; rosuvastatin, aspirin and clopidogrel capsules from Merck Specialities has also been fixed by the Authority.
The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified and notified by the NPPA. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers, said the price regulator.
It may be noted that the NPPA has notified the retail prices of 38 formulations as per the provisions to set prices of new drugs under the Drugs Prices Control Order (DPCO), 2013 in the previous meeting.
This include retail price for anti-diabetes combinations with various strengths of empagliflozin, linagliptin and metformin hydrochloride extended release from Corona Remedies; combination of empagliflozin, sitagliptin and metformin hydrochloride extended release USV Ltd, Micro Labs, and Aristo Pharmaceuticals; and empagliflozin and metformin hydrochloride combination from Eris Lifesciences, and Medley Pharmaceuticals has been fixed during the meeting.
The retail prices of new drugs, which are formulations launched by existing manufacturers of a medicine listed in National List of Essential Medicine (NLEM) by combining it with another drug, or by changing the strength or dosage or both of such medicine, are fixed by NPPA under DPCO, 2013, through this exercise.
